These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 9607124)

  • 1. Autoantibody inhibits binding of von Willebrand factor to glycoprotein Ib and collagen in multiple myeloma: recognition sites present on the A1 loop and A3 domains of von Willebrand factor.
    Mohri H; Hisanaga S; Mishima A; Fujimoto S; Uezono S; Okubo T
    Blood Coagul Fibrinolysis; 1998 Jan; 9(1):91-7. PubMed ID: 9607124
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Autoantibody selectively inhibits binding of von Willebrand factor to glycoprotein ib. Recognition site is located in the A1 loop of von Willebrand factor.
    Mohri H; Yamazaki E; Suzuki Z; Takano T; Yokota S; Okubo T
    Thromb Haemost; 1997 Apr; 77(4):760-6. PubMed ID: 9134656
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structure and function of the von Willebrand factor A1 domain: analysis with monoclonal antibodies reveals distinct binding sites involved in recognition of the platelet membrane glycoprotein Ib-IX-V complex and ristocetin-dependent activation.
    De Luca M; Facey DA; Favaloro EJ; Hertzberg MS; Whisstock JC; McNally T; Andrews RK; Berndt MC
    Blood; 2000 Jan; 95(1):164-72. PubMed ID: 10607699
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acquired von Willebrand disease caused by an autoantibody selectively inhibiting the binding of von Willebrand factor to collagen.
    van Genderen PJ; Vink T; Michiels JJ; van 't Veer MB; Sixma JJ; van Vliet HH
    Blood; 1994 Nov; 84(10):3378-84. PubMed ID: 7949092
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A new mutation, S1285F, within the A1 loop of von Willebrand factor induces a conformational change in A1 loop with abnormal binding to platelet GPIb and botrocetin causing type 2M von Willebrand disease.
    Stepanian A; Ribba AS; Lavergne JM; Fressinaud E; Juhan-Vague I; Mazurier C; Girma JP; Meyer D
    Br J Haematol; 2003 Feb; 120(4):643-51. PubMed ID: 12588351
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Type 2M von Willebrand disease: F606I and I662F mutations in the glycoprotein Ib binding domain selectively impair ristocetin- but not botrocetin-mediated binding of von Willebrand factor to platelets.
    Hillery CA; Mancuso DJ; Evan Sadler J; Ponder JW; Jozwiak MA; Christopherson PA; Cox Gill J; Paul Scott J; Montgomery RR
    Blood; 1998 Mar; 91(5):1572-81. PubMed ID: 9473222
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Conformational changes in the A3 domain of von Willebrand factor modulate the interaction of the A1 domain with platelet glycoprotein Ib.
    Obert B; Houllier A; Meyer D; Girma JP
    Blood; 1999 Mar; 93(6):1959-68. PubMed ID: 10068669
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acquired von Willebrand disease associated with multiple myeloma; characterization of an inhibitor to von Willebrand factor.
    Mohri H; Tanabe J; Ohtsuka M; Yoshida M; Motomura S; Nishida S; Fujimura Y; Okubo T
    Blood Coagul Fibrinolysis; 1995 Sep; 6(6):561-6. PubMed ID: 7578899
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of a myeloma patient with a life-threatening hemorrhagic diathesis: presence of a lambda dimer protein inhibiting shear-induced platelet aggregation by binding to the A1 domain of von Willebrand factor.
    Shinagawa A; Kojima H; Berndt MC; Kaneko S; Suzukawa K; Hasegawa Y; Shigeta O; Nagasawa T
    Thromb Haemost; 2005 May; 93(5):889-96. PubMed ID: 15886805
    [TBL] [Abstract][Full Text] [Related]  

  • 10. N1421K mutation in the glycoprotein Ib binding domain impairs ristocetin- and botrocetin-mediated binding of von Willebrand factor to platelets.
    Lanke E; Kristoffersson AC; Isaksson C; Holmberg L; Lethagen S
    Eur J Haematol; 2008 Nov; 81(5):384-90. PubMed ID: 18637125
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical significance of inhibitors in acquired von Willebrand syndrome.
    Mohri H; Motomura S; Kanamori H; Matsuzaki M; Watanabe S; Maruta A; Kodama F; Okubo T
    Blood; 1998 May; 91(10):3623-9. PubMed ID: 9572997
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of the binding site for an alloantibody to von Willebrand factor which inhibits binding to glycoprotein Ib within the amino-terminal region flanking the A1 domain.
    Shibata M; Shima M; Fujimura Y; Takahashi Y; Nakai H; Sakurai Y; Asatani M; Nomura A; Take H; Giddings JC; Yoshioka A
    Thromb Haemost; 1999 May; 81(5):793-8. PubMed ID: 10365755
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mapping and functional studies of two alloantibodies developed in patients with type 3 von Willebrand disease.
    Tout H; Obert B; Houllier A; Fressinaud E; Rothschild C; Meyer D; Girma JP
    Thromb Haemost; 2000 Feb; 83(2):274-81. PubMed ID: 10739386
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Isolation of the von Willebrand factor domain interacting with platelet glycoprotein Ib, heparin, and collagen and characterization of its three distinct functional sites.
    Mohri H; Yoshioka A; Zimmerman TS; Ruggeri ZM
    J Biol Chem; 1989 Oct; 264(29):17361-7. PubMed ID: 2477370
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Purification of botrocetin from Bothrops jararaca venom. Analysis of the botrocetin-mediated interaction between von Willebrand factor and the human platelet membrane glycoprotein Ib-IX complex.
    Andrews RK; Booth WJ; Gorman JJ; Castaldi PA; Berndt MC
    Biochemistry; 1989 Oct; 28(21):8317-26. PubMed ID: 2557900
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The arginine-552-cysteine (R1315C) mutation within the A1 loop of von Willebrand factor induces an abnormal folding with a loss of function resulting in type 2A-like phenotype of von Willebrand disease: study of 10 patients and mutated recombinant von Willebrand factor.
    Ribba AN; Hilbert L; Lavergne JM; Fressinaud E; Boyer-Neumann C; Ternisien C; Juhan-Vague I; Goudemand J; Girma J; Mazurier C; Meyer D
    Blood; 2001 Feb; 97(4):952-9. PubMed ID: 11159522
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Binding of the von Willebrand factor A1 domain to histone.
    Ward CM; Tetaz TJ; Andrews RK; Berndt MC
    Thromb Res; 1997 Jun; 86(6):469-77. PubMed ID: 9219327
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of murine anti-glycoprotein Ib monoclonal antibodies that differentiate between shear-induced and ristocetin/botrocetin-induced glycoprotein Ib-von Willebrand factor interaction.
    Cauwenberghs N; Ajzenberg N; Vauterin S; Hoylaerts MF; Declerck PJ; Baruch D; Deckmyn H
    Haemostasis; 2000; 30(3):139-48. PubMed ID: 11014964
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Binding site on human von Willebrand factor of bitiscetin, a snake venom-derived platelet aggregation inducer.
    Matsui T; Hamako J; Matsushita T; Nakayama T; Fujimura Y; Titani K
    Biochemistry; 2002 Jun; 41(25):7939-46. PubMed ID: 12069583
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ristocetin and botrocetin involve two distinct domains of von Willebrand factor for binding to platelet membrane glycoprotein Ib.
    Girma JP; Takahashi Y; Yoshioka A; Diaz J; Meyer D
    Thromb Haemost; 1990 Oct; 64(2):326-32. PubMed ID: 1702906
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.